✦ LIBER ✦

Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma

✍ Scribed by Wood, L; Palmer, M; Hewitt, J; Urtasun, R; Bruera, E; Rapp, E; Thaell, JF

Book ID: 109837489
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 891 KB
Volume: 77
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1998.100

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III randomized double blind placeb

Phase III randomized double blind placebo controlled trial of cisplatin(P) and etoposide (E) plus megestrol acetate (M)/placebo in extensive stage small cell lung cancer (SCLC)

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Phase III, Randomized, Double-Blind, Pla

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer

✍ Paz-Ares, L. G.; Biesma, B.; Heigener, D.; von Pawel, J.; Eisen, T.; Bennouna, J 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 163 KB

Efficacy of bevacizumab plus erlotinib v

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

✍ Roy S Herbst; Rafat Ansari; Frederique Bustin; Patrick Flynn; Lowell Hart; Grego 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 338 KB